GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients ...

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

A systematic review found improved sleep quality and longer REM sleep after endoscopic surgery for chronic rhinosinusitis ...

GSK (NYSE:GSK) notched a solid regulatory win in Japan, with health authorities approving Exdensur for patients with severe ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...

(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and Welfare for severe asthma and chronic ...

Another common reason for nosebleeds is “digital manipulation, which is a nice way of saying nose picking or scratching your ...

Although most cases of nosebleeding are simple and not worrying, they should not occur if everything inside the nose is intact, according to Dr. Patricia Loftus ...

Symptoms often include facial pressure, congestion and fatigue — It affects about 37 million Americans each year — Infections ...